BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15068610)

  • 1. Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.
    Borchardt PE; Vriesendorp HM; Freedman RS; Quadri SM
    Cancer Biother Radiopharm; 2004 Feb; 19(1):43-51. PubMed ID: 15068610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralesional radiolabeled human monoclonal IgM in human tumor xenografts.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    Radiother Oncol; 1997 Sep; 44(3):283-93. PubMed ID: 9380829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    Cancer Biother Radiopharm; 2000 Feb; 15(1):53-64. PubMed ID: 10740653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
    Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
    Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
    PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R; Chen S; Haim S; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
    Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
    Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
    Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
    Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis.
    Quadri SM; Malik AB; Chu HB; Freedman RS; Vriesendorp HM
    J Nucl Med; 1996 Sep; 37(9):1545-51. PubMed ID: 8790216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
    Ning S; Trisler K; Wessels BW; Knox SJ
    Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
    O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
    Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy with 90Y-labeled monoclonal antibodies in a nude mouse ovarian cancer model.
    Kairemo K; Ljunggren K; Strand SE; Hiltunen J; Penttilä P; Nikula T; Laine A; Wahlström T
    Acta Oncol; 1993; 32(7-8):801-5. PubMed ID: 8305229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting and therapy of human glioma xenografts in vivo utilizing radiolabeled antibodies.
    Williams JA; Wessels BW; Edwards JA; Kopher KA; Wanek PM; Wharam MD; Order SE; Klein JL
    Cancer Res; 1990 Feb; 50(3 Suppl):974s-979s. PubMed ID: 2404587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
    Gerretsen M; Visser GW; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Cancer Res; 1993 Aug; 53(15):3524-9. PubMed ID: 8339258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
    Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z
    Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
    Schott ME; Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Cheng R; Kruper WJ; Fordyce W; Goeckeler W
    Cancer; 1994 Feb; 73(3 Suppl):993-8. PubMed ID: 8306291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.